Want to see JNJ full AI Analyst Report?

Johnson & Johnson (JNJ) Price & Analysis

28,311 Followers

JNJ Stock Chart & Stats

$234.18

-$4.08(-2.79%)

At close: Jan 08 4:00 PM EST

$234.18

-$4.08(-2.79%)

Day’s Range― - ―

52-Week Range$164.23 - $269.43

Previous CloseN/A

Volume3.80M

Average Volume (3M)8.55M

Market Cap

$603.27B

Enterprise Value$620.88K

Total Cash (Recent Filing)$22.05B

Total Debt (Recent Filing)$54.99B

Price to Earnings (P/E)29.4

Beta-0.02

Next Earnings

Oct 20, 2026

EPS Estimate

3.05

Next Dividend Ex-DateN/A

Dividend Yield2.05%

Share Statistics

EPS (TTM)8.67

Shares Outstanding2,407,217,000

10 Day Avg. Volume8,270,104

30 Day Avg. Volume8,554,824

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)6.18

Price to Sales (P/S)5.35

P/FCF Ratio25.59

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda<0.01

Forecast

1Y Price Target

$279.19

Price Target Upside19.22% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering17

EPS Forecast (FY)11.67

Revenue Forecast (FY)$101.06B

Bulls Say, Bears Say

Bulls Say

Broad, High‑growth Product Portfolio And Successful LaunchesA diversified set of new and growing products reduces reliance on any single franchise and supports durable revenue growth. Rapid uptake and payor coverage for recent launches (ICOTYDE, INLEXZO) signal sustainable adoption, improving mid‑term revenue visibility and easing replacement of legacy declines.

High And Resilient Profitability MarginsConsistently strong gross and operating margins indicate structural pricing power, efficient R&D/SG&A leverage and a defensible cost base. High margins provide buffer against cyclical volume swings and fund reinvestment, supporting sustained earnings power over the next several quarters.

Strong Absolute Cash Generation And Cash BufferLarge, repeatable cash generation and a sizable cash treasury provide durable financial flexibility to fund launches, M&A (e.g., Firefly Bio), dividends and buybacks. High cash levels support capital allocation consistency and reduce funding risk through industry cycles.

Bears Say

Material Biosimilar Erosion Of Legacy Franchise (STELARA)A >50% decline from biosimilar competition highlights vulnerability of legacy biologics to rapid market share loss. Such steep erosion pressures topline predictability and forces sustained investment in replacements; timing/size of offsets from new launches remain execution‑dependent.

MedTech Segment Faces Structural And Competitive PressuresMedTech performance hinges on procedural volumes, physician preferences and device technology cycles. Competitive innovation (e.g., PFA) and regional inventory or policy effects can depress revenue for quarters to years, making recovery uncertain and increasing capital intensity for product refreshes.

Weaker FCF Momentum And Cash Conversion Timing IssuesDeclining FCF momentum and operating cash flow that is materially below net income point to less consistent cash conversion. This can constrain discretionary spend, extend payback periods for launches/M&A, and raise sensitivity to working‑capital shocks over the medium term.

Johnson & Johnson News

Johnson & Johnson Continues Recovery After Green Light Given to ‘Next Era’ Robotic Surgeon

Shares in medical group Johnson & Johnson ($JNJ) were healthier today after it received the green light to...

19h ago

JNJ

MDT

Johnson & Johnson Stock (JNJ) Rises as Robotic Surgery Device Is Approved

The approval opens a new market for the healthcare company. ...

19h ago

JNJ

MDT

Trump Trade: U.S. to impose 100% tariff on imported generic drugs

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

20h ago

AAL

Johnson & Johnson receives FDA Marketing Authorization in U.S. for OTTAVA

Johnson & Johnson announced that the U.S. Food and Drug Administration, FDA, has granted De Novo authorization for...

23h ago

JNJ

Trump to set 100% tariff on generic drugs brought into U.S. starting in 2028

U.S. President Donald Trump said in a post on Truth Social, “Effective August 1st, 2026, all Generic Drugs...

1d ago

AZN

BMY

3 ‘Strong Buy’ Dividend Aristocrat Stocks for Steady Cash Flow, 7/21/26

Investors looking for steady cash payments can bank on NextEra ($NEE), Coca-Cola ($KO), and Johnson & Johnson ($JNJ)....

2d ago

JNJ

Johnson & Johnson upgraded to Buy at Freedom Broker after strong quarter

As previously reported, Freedom Broker analyst Ilya Zubkov upgraded Johnson & Johnson to Buy from Hold with a...

7d ago

JNJ

Johnson & Johnson upgraded to Buy from Hold at Freedom Broker

Freedom Broker upgraded Johnson & Johnson to Buy from Hold with a $280 price target Published first on...

7d ago

JNJ

Johnson & Johnson price target raised to $305 from $265 at Scotiabank

Scotiabank raised the firm’s price target on Johnson & Johnson to $305 from $265 and keeps an Outperform...

7d ago

JNJ

Johnson & Johnson price target raised to $265 from $258 at Raymond James

Raymond James raised the firm’s price target on Johnson & Johnson to $265 from $258 and keeps an...

7d ago

JNJ

Johnson & Johnson price target raised to $282 from $275 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Johnson & Johnson to $282 from $275 and keeps a...

7d ago

JNJ

Johnson & Johnson price target raised to $270 from $260 at JPMorgan

JPMorgan analyst Chris Schott raised the firm’s price target on Johnson & Johnson to $270 from $260 and...

7d ago

JNJ

Johnson & Johnson price target raised to $294 from $284 at Morgan Stanley

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Johnson & Johnson to $294 from $284...

7d ago

JNJ

Johnson & Johnson Stock (JNJ) Falls despite Q2 Beat, Higher Sales Forecast for 2026

Shares in Johnson & Johnson ($JNJ) dropped about 3% early Wednesday. This came even though the U.S. pharma...

8d ago

JNJ

JNJ FAQ

What was Johnson & Johnson’s price range in the past 12 months?

Johnson & Johnson lowest stock price was $164.23 and its highest was $269.43 in the past 12 months.

What is Johnson & Johnson’s market cap?

Johnson & Johnson’s market cap is $603.27B.

When is Johnson & Johnson’s upcoming earnings report date?

Johnson & Johnson’s upcoming earnings report date is Oct 20, 2026 which is in 89 days.

How were Johnson & Johnson’s earnings last quarter?

Johnson & Johnson released its earnings results on Jul 15, 2026. The company reported $2.9 earnings per share for the quarter, beating the consensus estimate of $2.855 by $0.045.

Is Johnson & Johnson overvalued?

According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Johnson & Johnson pay dividends?

Johnson & Johnson pays a Quarterly dividend of $1.34 which represents an annual dividend yield of 2.05%. See more information on Johnson & Johnson dividends here

What is Johnson & Johnson’s EPS estimate?

Johnson & Johnson’s EPS estimate is 3.05.

How many shares outstanding does Johnson & Johnson have?

Johnson & Johnson has 2,407,217,000 shares outstanding.

What happened to Johnson & Johnson’s price movement after its last earnings report?

Johnson & Johnson reported an EPS of $2.9 in its last earnings report, beating expectations of $2.855. Following the earnings report the stock price went down -2.691%.

Which hedge fund is a major shareholder of Johnson & Johnson?

Currently, no hedge funds are holding shares in JNJ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Johnson & Johnson Stock Smart Score

Outperform

Company Description

Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson (JNJ) Earnings & Revenues

Historic Earnings Reports

JNJ Sales Breakdown

64.12% Innovative Medicine

35.88% MedTech

JNJ Stock 12 Month Forecast

Average Price Target

$279.19

▲(19.22% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"151":"$151","306":"$306","189.75":"$189.8","228.5":"$228.5","267.25":"$267.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":305,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$305.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":279.1875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$279.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":255,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$255.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[151,189.75,228.5,267.25,306],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,253.98,257.9046153846154,261.8292307692308,265.75384615384615,269.67846153846153,273.6030769230769,277.5276923076923,281.45230769230767,285.37692307692305,289.3015384615385,293.22615384615386,297.15076923076924,301.0753846153846,{"y":305,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,253.98,255.91903846153846,257.8580769230769,259.7971153846154,261.73615384615385,263.6751923076923,265.61423076923074,267.5532692307692,269.4923076923077,271.43134615384616,273.37038461538464,275.30942307692305,277.2484615384615,{"y":279.1875,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,253.98,254.05846153846153,254.13692307692307,254.2153846153846,254.29384615384615,254.3723076923077,254.45076923076923,254.52923076923076,254.6076923076923,254.68615384615384,254.76461538461538,254.84307692307692,254.92153846153846,{"y":255,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":152.993,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.189,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.121,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.898,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.685,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.254,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.855,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":229.529,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":248.56,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":244.12,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":227.19,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":223.51,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":253.98,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >